DV
Dividend Vision

CELU — Celularity Inc

Celularity Inc (CELU)

Total return is -99.3% over the past 7 years, 292.1 points behind SPY at 192.8%. Its deepest 1-year drawdown was 85.6%.

Celularity Inc. is a cellular and regenerative medicine company developing off-the-shelf cell therapy products to address aging-related diseases, with three operating segments: Cell Therapy (including candidates like PDA-001 for Crohn's disease and PDA-002 for multiple sclerosis and other conditions), Degenerative Disease, and BioBanking (which collects and stores umbilical cord and placental tissue under the LifebankUSA brand, and produces surgical and wound care products). The company does not currently distribute dividends. As a clinical-stage biopharma company, Celularity appeals primarily to growth-oriented investors seeking exposure to regenerative medicine rather than those focused on current income.

CELU key facts

Asset type
Stock
Asset class
Equity
Inception date
08/08/2019
Last close
$0.70
Market cap
$22,586,534
Average volume
11415.0
Beta
0.538
Payout ratio
0.0
Forward P/E
0.0
EPS
$-3.59